Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
3 recherche sur le mot-clé 'cost analysis'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Parent coaching intervention for children with suspected autism spectrum disorder: Cost analysis / Kate TSIPLOVA in Research in Autism Spectrum Disorders, 93 (May 2022)
[article]
Titre : Parent coaching intervention for children with suspected autism spectrum disorder: Cost analysis Type de document : Texte imprimé et/ou numérique Auteurs : Kate TSIPLOVA, Auteur ; Jathishinie JEGATHISAWARAN, Auteur ; Pat MIRENDA, Auteur ; Karen KALYNCHUK, Auteur ; Paola COLOZZO, Auteur ; Veronica SMITH, Auteur ; Wendy J. UNGAR, Auteur Article en page(s) : 101949 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Parent coaching Toddlers Service use Cost analysis Index. décimale : PER Périodiques Résumé : Background Parent coaching interventions for young children suspected of having autism spectrum disorder (ASD) have shown promise. The objectives were to measure the costs of parent coaching and the pre-diagnosis utilization of services and treatments related to autism and to compare costs between families who received parent coaching (PC) and those who received enhanced community treatment (ECT). Methods This analysis was conducted prospectively alongside a randomized comparative effectiveness trial of a PC intervention in British Columbia, Canada. Twenty-four participants were randomly assigned to the PC group and received 24 weeks of coaching support and 25 participants were assigned to the ECT group. Families in both groups also received health, education and community services. Parent-reported service utilization was collected for the 6 months prior to initiation of parent coaching and for the period coinciding with receipt of one of the two interventions. Services were costed from the public payer (i.e., provincial government) and societal perspectives; the latter included out-of-pocket family costs, parental time losses due to caregiving, and public payer costs. Results Families in the PC group used fewer services than did those in the ECT group. The estimated incremental mean cost per family over two time periods for PC compared to ECT was $2515 CAD (95% CI: ? 1302, 5071) from the public payer perspective and $6994 CAD (95% CI: ? 4395, 19,299) from the societal perspective. Conclusions The findings can be used to inform funding and policy decision-making to enhance the treatment options available for young children awaiting an ASD diagnosis. En ligne : https://doi.org/10.1016/j.rasd.2022.101949 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475
in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101949[article] Parent coaching intervention for children with suspected autism spectrum disorder: Cost analysis [Texte imprimé et/ou numérique] / Kate TSIPLOVA, Auteur ; Jathishinie JEGATHISAWARAN, Auteur ; Pat MIRENDA, Auteur ; Karen KALYNCHUK, Auteur ; Paola COLOZZO, Auteur ; Veronica SMITH, Auteur ; Wendy J. UNGAR, Auteur . - 101949.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101949
Mots-clés : Autism spectrum disorder Parent coaching Toddlers Service use Cost analysis Index. décimale : PER Périodiques Résumé : Background Parent coaching interventions for young children suspected of having autism spectrum disorder (ASD) have shown promise. The objectives were to measure the costs of parent coaching and the pre-diagnosis utilization of services and treatments related to autism and to compare costs between families who received parent coaching (PC) and those who received enhanced community treatment (ECT). Methods This analysis was conducted prospectively alongside a randomized comparative effectiveness trial of a PC intervention in British Columbia, Canada. Twenty-four participants were randomly assigned to the PC group and received 24 weeks of coaching support and 25 participants were assigned to the ECT group. Families in both groups also received health, education and community services. Parent-reported service utilization was collected for the 6 months prior to initiation of parent coaching and for the period coinciding with receipt of one of the two interventions. Services were costed from the public payer (i.e., provincial government) and societal perspectives; the latter included out-of-pocket family costs, parental time losses due to caregiving, and public payer costs. Results Families in the PC group used fewer services than did those in the ECT group. The estimated incremental mean cost per family over two time periods for PC compared to ECT was $2515 CAD (95% CI: ? 1302, 5071) from the public payer perspective and $6994 CAD (95% CI: ? 4395, 19,299) from the societal perspective. Conclusions The findings can be used to inform funding and policy decision-making to enhance the treatment options available for young children awaiting an ASD diagnosis. En ligne : https://doi.org/10.1016/j.rasd.2022.101949 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475 Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism / T. W. FRAZIER in Autism Research, 14-6 (June 2021)
[article]
Titre : Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism Type de document : Texte imprimé et/ou numérique Auteurs : T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur Article en page(s) : p.1271-1283 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis Autistic Disorder Biomarkers Child Early Diagnosis Humans Mass Screening United States autism spectrum disorder biomarkers cost analysis early diagnosis evidence-based assessment developer of the eye tracking test that was used in the EBM analysis. Thomas W. Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker's honorarium from Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and Frank A. Middleton are co?developers of the saliva RNA based autism test that is used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant Biosciences. Daniel L. Coury has received federal funding or research support from National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and Stalicla SA and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for the Clarifi ASD saliva test. Index. décimale : PER Périodiques Résumé : Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan. En ligne : http://dx.doi.org/10.1002/aur.2498 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449
in Autism Research > 14-6 (June 2021) . - p.1271-1283[article] Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism [Texte imprimé et/ou numérique] / T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur . - p.1271-1283.
Langues : Anglais (eng)
in Autism Research > 14-6 (June 2021) . - p.1271-1283
Mots-clés : Autism Spectrum Disorder/diagnosis Autistic Disorder Biomarkers Child Early Diagnosis Humans Mass Screening United States autism spectrum disorder biomarkers cost analysis early diagnosis evidence-based assessment developer of the eye tracking test that was used in the EBM analysis. Thomas W. Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker's honorarium from Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and Frank A. Middleton are co?developers of the saliva RNA based autism test that is used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant Biosciences. Daniel L. Coury has received federal funding or research support from National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and Stalicla SA and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for the Clarifi ASD saliva test. Index. décimale : PER Périodiques Résumé : Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan. En ligne : http://dx.doi.org/10.1002/aur.2498 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003-2015 / S. H. ZUVEKAS in Journal of Autism and Developmental Disorders, 51-8 (August 2021)
[article]
Titre : Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003-2015 Type de document : Texte imprimé et/ou numérique Auteurs : S. H. ZUVEKAS, Auteur ; S. D. GROSSE, Auteur ; T. A. LAVELLE, Auteur ; M. J. MAENNER, Auteur ; P. DIETZ, Auteur ; X. JI, Auteur Article en page(s) : p.2950-2958 Langues : Anglais (eng) Mots-clés : Adolescent Autism Spectrum Disorder/diagnosis/economics/therapy Child Child, Preschool Female Health Care Costs Health Expenditures Humans Male United States Autism spectrum disorder Cost analysis Health economics Health services research article to disclose. Index. décimale : PER Périodiques Résumé : Published healthcare cost estimates for children with autism spectrum disorder (ASD) vary widely. One possible contributor is different methods of case ascertainment. In this study, ASD case status was determined using two sources of parent reports among 45,944 children ages 3-17 years in the Medical Expenditure Panel Survey (MEPS) linked to the National Health Interview Survey (NHIS) Sample Child Core questionnaire. In a two-part regression model, the incremental annual per-child cost of ASD relative to no ASD diagnosis was $3930 (2018 US dollars) using ASD case status from the NHIS Child Core and $5621 using current-year ASD case status from MEPS. Both estimates are lower than some published estimates but still represent substantial costs to the US healthcare system. En ligne : http://dx.doi.org/10.1007/s10803-020-04704-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=453
in Journal of Autism and Developmental Disorders > 51-8 (August 2021) . - p.2950-2958[article] Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003-2015 [Texte imprimé et/ou numérique] / S. H. ZUVEKAS, Auteur ; S. D. GROSSE, Auteur ; T. A. LAVELLE, Auteur ; M. J. MAENNER, Auteur ; P. DIETZ, Auteur ; X. JI, Auteur . - p.2950-2958.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 51-8 (August 2021) . - p.2950-2958
Mots-clés : Adolescent Autism Spectrum Disorder/diagnosis/economics/therapy Child Child, Preschool Female Health Care Costs Health Expenditures Humans Male United States Autism spectrum disorder Cost analysis Health economics Health services research article to disclose. Index. décimale : PER Périodiques Résumé : Published healthcare cost estimates for children with autism spectrum disorder (ASD) vary widely. One possible contributor is different methods of case ascertainment. In this study, ASD case status was determined using two sources of parent reports among 45,944 children ages 3-17 years in the Medical Expenditure Panel Survey (MEPS) linked to the National Health Interview Survey (NHIS) Sample Child Core questionnaire. In a two-part regression model, the incremental annual per-child cost of ASD relative to no ASD diagnosis was $3930 (2018 US dollars) using ASD case status from the NHIS Child Core and $5621 using current-year ASD case status from MEPS. Both estimates are lower than some published estimates but still represent substantial costs to the US healthcare system. En ligne : http://dx.doi.org/10.1007/s10803-020-04704-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=453